Nexavar (sorafenib) has been shown to significantly improve overall survival by 47.3% in a phase III trial in patients with either advanced hepatocellular carcinoma or primary liver cancer
Filed under: kinase | Tagged: bayer, multikinase, Nexavar, onyx, phase iii, sorafenib
Name
Mail (will not be published)
Website
Notify me of follow-up comments via email.
